Herein, we report one critical target of USP3, SMARCA5 and the specific mechanism of USP3-mediated deubiquitination of SMARCA5 in Docetaxel-inducing DNA damage, suggesting that USP3 may be a promising target for anticancer therapy in prostate cancer. This evidence concerns the gene USP3 and prostate carcinoma.